Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528302 | 0.86 | MET (0.51) | METTP53MEN1KMT2AGRIN1 | |
| SCHEMBL25180870 | 0.85 | P2RX7 (0.40) | METMEN1KMT2AP2RX7GRIN1 | |
| SCHEMBL30420038 | 0.85 | P2RX7 (0.40) | METMEN1KMT2AP2RX7GRIN1 | |
| SCHEMBL23528305 | 0.85 | GRIN1 (0.44) | TP53MEN1KMT2AP2RX7GRIN1 | |
| SCHEMBL25438986 | 0.84 | GRIN2B (0.42) | METP2RX7GRIN1GRIN2B | |
| SCHEMBL23528328 | 0.83 | PDE4A (0.47) | METTP53MEN1KMT2AP2RX7 | |
| SCHEMBL23528540 | 0.83 | MET (0.44) | METTP53MEN1KMT2AGRIN1 | |
| SCHEMBL25418980 | 0.82 | MET (0.39) | METTP53MEN1KMT2AP2RX7 | |
| SCHEMBL23528368 | 0.82 | MET (0.45) | METTP53MEN1KMT2AGRIN1 | |
| SCHEMBL23528316 | 0.82 | MET (0.39) | METTP53MEN1KMT2AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388564-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | EDGEWISE THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4522599-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119317621-A | Process for preparing pyridazinone compounds | 艾知怀斯治疗学公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023220180-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | EDGEWISE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388564-A1 | METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS | MUSK, SMN1; SMN2, PAX3 | MET 2374/4885TP53 4865/4885MEN1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.